Online inquiry

IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10814MR)

This product GTTS-WQ10814MR is a type of mRNA modified with 2-Thio-UTP, which ecodes the monoclonal antibody that targets PD-L1; TGFBR2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267706.2; NM_001024847.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126; 7048
UniProt ID Q9NZQ7; P37173
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ10814MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15275MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Theraloc
GTTS-WQ652MR IVTScrip™ mRNA-Anti-AOC3, 8c10(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 8c10
GTTS-WQ8775MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA IBI-306
GTTS-WQ2322MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALXN6000
GTTS-WQ5554MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CDP7657
GTTS-WQ8888MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ1535MR IVTScrip™ mRNA-Anti-MSTN, ACE-031(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACE-031
GTTS-WQ4683MR IVTScrip™ mRNA-Anti-MSTN, BMS-986089(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-986089
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW